Researchers are still struggling to find effective, easy-to-use drugs to treat Covid-19. Here’s why.
. The best medicines for early treatment are cumbersome to administer, and drugs for those in the hospital can only do so much for patients who are already severely ill.
“We’re really limited, to be honest,” says Daniel Griffin, chief of infectious disease at healthcare provider network ProHealth New York. “We do not have any dramatic treatments.” A long list of factors played into the checkered development of drugs to treat Covid-19 cases—exposing flaws in the infrastructure of medical research and healthcare, particularly in fighting a fast-moving pandemic.
Federal officials concentrated their resources on quickly developing vaccines, with success. However, a relative dearth of drug research focused on coronaviruses, despite previous outbreaks, held back a fast response on treatments. Scattered U.S. clinical trials competed against each other for patients. When effective yet hard-to-administer drugs were developed, a fragmented American healthcare system struggled to deliver them to patients.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Outbreaks of covid-19 leave South-East Asia with little policy roomOn July 20th the Asian Development Bank pared back its growth forecasts for South-East Asia. It now expects an expansion of 4% this year, compared with an earlier forecast of 4.4%
Consulte Mais informação »
Leopardo de las nieves Ramil tiene COVID-19 en el Zoo de San DiegoEl personal del zoológico está investigando cómo se infectó
Consulte Mais informação »
Covid-19 Vaccine Holdouts Face Restrictions in Europe as Delta Variant SpreadsWorried about the rapid spread of the Delta variant, governments are nudging, and in some cases, pushing, people to get vaccinated by introducing restrictions to daily life for those without a Covid-19 shot.
Consulte Mais informação »
WSJ News Exclusive | Covid-19 Pill Race Heats Up as Japanese Firm Vies With Pfizer, MerckJapan’s Shionogi has started human trials for a once-a-day drug designed to neutralize the coronavirus in less than a week as Pfizer and Merck carry out later-stage tests.
Consulte Mais informação »
Las personas vacunadas pueden contraer infecciones de COVID-19: ¿Qué tan preocupados deberíamos estar?En junio, el 20% de los casos de coronavirus del condado de Los Ángeles se dieron entre residentes totalmente vacunados. Pero eso no cuenta la historia completa.
Consulte Mais informação »